4CPS-057 Searching for a treatment for peripheral tissue ischemia in newborns: a case report

Background and ImportancePeripheral tissue ischemia (PTI) is a complication of vascular catheterisation in newborns. Conservative measures are often insufficient. Topical nitroglycerin has been used off-label as salvage therapy. We were requested 2% topical nitroglycerin ointment (TNO) as a compound...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of hospital pharmacy. Science and practice 2023-03, Vol.30 (Suppl 1), p.A42-A43
Hauptverfasser: Díaz Perales, R, Yunquera Romero, L, Saldaña Soria, R, Gallego Fernández, C
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A43
container_issue Suppl 1
container_start_page A42
container_title European journal of hospital pharmacy. Science and practice
container_volume 30
creator Díaz Perales, R
Yunquera Romero, L
Saldaña Soria, R
Gallego Fernández, C
description Background and ImportancePeripheral tissue ischemia (PTI) is a complication of vascular catheterisation in newborns. Conservative measures are often insufficient. Topical nitroglycerin has been used off-label as salvage therapy. We were requested 2% topical nitroglycerin ointment (TNO) as a compounding formula for PTI in two prematures. Due to the shortage of raw material, an effective and safe alternative had to be sought out.Aim and ObjectivesTo identify an alternative for 2% TNO as therapy for PTI, and thus, to describe the effectiveness and security of applying 0,4% rectal nitroglycerin ointment (RNO) in the affected areas.Material and MethodsProspective study between January-June 2022, of 2 newborns with PTI. Patient 1: female, 31+5; 2 days, 1500g, ecchymosis in 4 fingers. Patient 2: female, 24+6; 5days , 595g, marked necrosis in the pads of 5 fingers.The manufacturing laboratory and other hospitals were contacted to find out the availability of the raw material. We also consulted the Spanish Pharmacy Preparations and Compounding Group, and the Spanish Agency for Medicines and Medical Products (AEMPS) database for alternatives. We systematically searched MEDLINE, PubMed, Embase, Google Scholar. A close follow-up was carried out in coordination with paediatricians, and electronic prescription and computerised medical records were consulted daily, to evaluate effectiveness and security.ResultsDue to the lack of raw material and alternatives in its preparation, other marketed pharmaceutical forms of nitroglycerin were evaluated (intravenous solution, transdermal patches, sublingual tablets, rectal ointment and sublingual spray). Application of 0.4% RNO in the affected areas was considered the most effective, safest, easy to dose, and quickest to acquire alternative.Patient1: ecchymosis completely disappeared in 48 hours of treatment. No adverse events, normal control of methaemoglobin. Good perfusion without vasoactives. Patient 2: 10 days to remit the marked necrosis. Well tolerated, initial slight drop in blood pressure, needing an increase of dopamine. Loss of the phalanges was avoided in both patients.Conclusion and RelevanceCommercialised 0.4% RNO in PTI was effective and safe in low birth weight premature newborns. However, it is necessary to be studied in more patients.Pharmacist’s role in the preparation, control and dispensing of medicines is essential, and its integration in the multidisciplinary team is crucial to ensure a quick response in em
doi_str_mv 10.1136/ejhpharm-2023-eahp.90
format Article
fullrecord <record><control><sourceid>proquest_bmj_j</sourceid><recordid>TN_cdi_proquest_journals_2790018335</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2790018335</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1170-3265e24b0448778c54367ebe582bc3191a3ab6b445395a3b6e77bd702afdcae13</originalsourceid><addsrcrecordid>eNpFkNtKAzEQhoMoWGofQQh4vTXJ5LDxToonKChUb12S7dRN6R5MdvHWG1_UJ7G1Hq5mBr75f_gIOeVsyjnoc1xXXeVinQkmIENXdVPLDshIMGkya7U8_NuVPiaTlIJnCiC3EuyIPMvZwyJjyny-fyzQxbIKzQtdtZE62kd0fY1N_313GENXYXQb2oeUBqQhlRXWwdHQ0AbffBubdLH9K11CGrFrY39CjlZuk3DyM8fk6frqcXabze9v7maX88xzblgGQisU0jMpc2PyUknQBj2qXPgSuOUOnNdeSgVWOfAajfFLw4RbLUuHHMbkbJ_bxfZ1wNQX63aIzbayEMYyxnMAtaX4nvL1-h_grNiZLH5NFjuTxc5kYRl8ATNnaks</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2790018335</pqid></control><display><type>article</type><title>4CPS-057 Searching for a treatment for peripheral tissue ischemia in newborns: a case report</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Díaz Perales, R ; Yunquera Romero, L ; Saldaña Soria, R ; Gallego Fernández, C</creator><creatorcontrib>Díaz Perales, R ; Yunquera Romero, L ; Saldaña Soria, R ; Gallego Fernández, C</creatorcontrib><description>Background and ImportancePeripheral tissue ischemia (PTI) is a complication of vascular catheterisation in newborns. Conservative measures are often insufficient. Topical nitroglycerin has been used off-label as salvage therapy. We were requested 2% topical nitroglycerin ointment (TNO) as a compounding formula for PTI in two prematures. Due to the shortage of raw material, an effective and safe alternative had to be sought out.Aim and ObjectivesTo identify an alternative for 2% TNO as therapy for PTI, and thus, to describe the effectiveness and security of applying 0,4% rectal nitroglycerin ointment (RNO) in the affected areas.Material and MethodsProspective study between January-June 2022, of 2 newborns with PTI. Patient 1: female, 31+5; 2 days, 1500g, ecchymosis in 4 fingers. Patient 2: female, 24+6; 5days , 595g, marked necrosis in the pads of 5 fingers.The manufacturing laboratory and other hospitals were contacted to find out the availability of the raw material. We also consulted the Spanish Pharmacy Preparations and Compounding Group, and the Spanish Agency for Medicines and Medical Products (AEMPS) database for alternatives. We systematically searched MEDLINE, PubMed, Embase, Google Scholar. A close follow-up was carried out in coordination with paediatricians, and electronic prescription and computerised medical records were consulted daily, to evaluate effectiveness and security.ResultsDue to the lack of raw material and alternatives in its preparation, other marketed pharmaceutical forms of nitroglycerin were evaluated (intravenous solution, transdermal patches, sublingual tablets, rectal ointment and sublingual spray). Application of 0.4% RNO in the affected areas was considered the most effective, safest, easy to dose, and quickest to acquire alternative.Patient1: ecchymosis completely disappeared in 48 hours of treatment. No adverse events, normal control of methaemoglobin. Good perfusion without vasoactives. Patient 2: 10 days to remit the marked necrosis. Well tolerated, initial slight drop in blood pressure, needing an increase of dopamine. Loss of the phalanges was avoided in both patients.Conclusion and RelevanceCommercialised 0.4% RNO in PTI was effective and safe in low birth weight premature newborns. However, it is necessary to be studied in more patients.Pharmacist’s role in the preparation, control and dispensing of medicines is essential, and its integration in the multidisciplinary team is crucial to ensure a quick response in emergency situations.References and/or AcknowledgementsConflict of InterestNo conflict of interest</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2023-eahp.90</identifier><language>eng</language><publisher>London: British Medical Journal Publishing Group</publisher><subject>Case reports ; Conflicts of interest ; Ischemia ; Raw materials ; Section 4: Clinical pharmacy services</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A42-A43</ispartof><rights>European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2023 European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Díaz Perales, R</creatorcontrib><creatorcontrib>Yunquera Romero, L</creatorcontrib><creatorcontrib>Saldaña Soria, R</creatorcontrib><creatorcontrib>Gallego Fernández, C</creatorcontrib><title>4CPS-057 Searching for a treatment for peripheral tissue ischemia in newborns: a case report</title><title>European journal of hospital pharmacy. Science and practice</title><addtitle>Eur J Hosp Pharm</addtitle><description>Background and ImportancePeripheral tissue ischemia (PTI) is a complication of vascular catheterisation in newborns. Conservative measures are often insufficient. Topical nitroglycerin has been used off-label as salvage therapy. We were requested 2% topical nitroglycerin ointment (TNO) as a compounding formula for PTI in two prematures. Due to the shortage of raw material, an effective and safe alternative had to be sought out.Aim and ObjectivesTo identify an alternative for 2% TNO as therapy for PTI, and thus, to describe the effectiveness and security of applying 0,4% rectal nitroglycerin ointment (RNO) in the affected areas.Material and MethodsProspective study between January-June 2022, of 2 newborns with PTI. Patient 1: female, 31+5; 2 days, 1500g, ecchymosis in 4 fingers. Patient 2: female, 24+6; 5days , 595g, marked necrosis in the pads of 5 fingers.The manufacturing laboratory and other hospitals were contacted to find out the availability of the raw material. We also consulted the Spanish Pharmacy Preparations and Compounding Group, and the Spanish Agency for Medicines and Medical Products (AEMPS) database for alternatives. We systematically searched MEDLINE, PubMed, Embase, Google Scholar. A close follow-up was carried out in coordination with paediatricians, and electronic prescription and computerised medical records were consulted daily, to evaluate effectiveness and security.ResultsDue to the lack of raw material and alternatives in its preparation, other marketed pharmaceutical forms of nitroglycerin were evaluated (intravenous solution, transdermal patches, sublingual tablets, rectal ointment and sublingual spray). Application of 0.4% RNO in the affected areas was considered the most effective, safest, easy to dose, and quickest to acquire alternative.Patient1: ecchymosis completely disappeared in 48 hours of treatment. No adverse events, normal control of methaemoglobin. Good perfusion without vasoactives. Patient 2: 10 days to remit the marked necrosis. Well tolerated, initial slight drop in blood pressure, needing an increase of dopamine. Loss of the phalanges was avoided in both patients.Conclusion and RelevanceCommercialised 0.4% RNO in PTI was effective and safe in low birth weight premature newborns. However, it is necessary to be studied in more patients.Pharmacist’s role in the preparation, control and dispensing of medicines is essential, and its integration in the multidisciplinary team is crucial to ensure a quick response in emergency situations.References and/or AcknowledgementsConflict of InterestNo conflict of interest</description><subject>Case reports</subject><subject>Conflicts of interest</subject><subject>Ischemia</subject><subject>Raw materials</subject><subject>Section 4: Clinical pharmacy services</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpFkNtKAzEQhoMoWGofQQh4vTXJ5LDxToonKChUb12S7dRN6R5MdvHWG1_UJ7G1Hq5mBr75f_gIOeVsyjnoc1xXXeVinQkmIENXdVPLDshIMGkya7U8_NuVPiaTlIJnCiC3EuyIPMvZwyJjyny-fyzQxbIKzQtdtZE62kd0fY1N_313GENXYXQb2oeUBqQhlRXWwdHQ0AbffBubdLH9K11CGrFrY39CjlZuk3DyM8fk6frqcXabze9v7maX88xzblgGQisU0jMpc2PyUknQBj2qXPgSuOUOnNdeSgVWOfAajfFLw4RbLUuHHMbkbJ_bxfZ1wNQX63aIzbayEMYyxnMAtaX4nvL1-h_grNiZLH5NFjuTxc5kYRl8ATNnaks</recordid><startdate>20230323</startdate><enddate>20230323</enddate><creator>Díaz Perales, R</creator><creator>Yunquera Romero, L</creator><creator>Saldaña Soria, R</creator><creator>Gallego Fernández, C</creator><general>British Medical Journal Publishing Group</general><general>BMJ Publishing Group LTD</general><scope>K9.</scope></search><sort><creationdate>20230323</creationdate><title>4CPS-057 Searching for a treatment for peripheral tissue ischemia in newborns: a case report</title><author>Díaz Perales, R ; Yunquera Romero, L ; Saldaña Soria, R ; Gallego Fernández, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1170-3265e24b0448778c54367ebe582bc3191a3ab6b445395a3b6e77bd702afdcae13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Case reports</topic><topic>Conflicts of interest</topic><topic>Ischemia</topic><topic>Raw materials</topic><topic>Section 4: Clinical pharmacy services</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Díaz Perales, R</creatorcontrib><creatorcontrib>Yunquera Romero, L</creatorcontrib><creatorcontrib>Saldaña Soria, R</creatorcontrib><creatorcontrib>Gallego Fernández, C</creatorcontrib><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Díaz Perales, R</au><au>Yunquera Romero, L</au><au>Saldaña Soria, R</au><au>Gallego Fernández, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>4CPS-057 Searching for a treatment for peripheral tissue ischemia in newborns: a case report</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><stitle>Eur J Hosp Pharm</stitle><date>2023-03-23</date><risdate>2023</risdate><volume>30</volume><issue>Suppl 1</issue><spage>A42</spage><epage>A43</epage><pages>A42-A43</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>Background and ImportancePeripheral tissue ischemia (PTI) is a complication of vascular catheterisation in newborns. Conservative measures are often insufficient. Topical nitroglycerin has been used off-label as salvage therapy. We were requested 2% topical nitroglycerin ointment (TNO) as a compounding formula for PTI in two prematures. Due to the shortage of raw material, an effective and safe alternative had to be sought out.Aim and ObjectivesTo identify an alternative for 2% TNO as therapy for PTI, and thus, to describe the effectiveness and security of applying 0,4% rectal nitroglycerin ointment (RNO) in the affected areas.Material and MethodsProspective study between January-June 2022, of 2 newborns with PTI. Patient 1: female, 31+5; 2 days, 1500g, ecchymosis in 4 fingers. Patient 2: female, 24+6; 5days , 595g, marked necrosis in the pads of 5 fingers.The manufacturing laboratory and other hospitals were contacted to find out the availability of the raw material. We also consulted the Spanish Pharmacy Preparations and Compounding Group, and the Spanish Agency for Medicines and Medical Products (AEMPS) database for alternatives. We systematically searched MEDLINE, PubMed, Embase, Google Scholar. A close follow-up was carried out in coordination with paediatricians, and electronic prescription and computerised medical records were consulted daily, to evaluate effectiveness and security.ResultsDue to the lack of raw material and alternatives in its preparation, other marketed pharmaceutical forms of nitroglycerin were evaluated (intravenous solution, transdermal patches, sublingual tablets, rectal ointment and sublingual spray). Application of 0.4% RNO in the affected areas was considered the most effective, safest, easy to dose, and quickest to acquire alternative.Patient1: ecchymosis completely disappeared in 48 hours of treatment. No adverse events, normal control of methaemoglobin. Good perfusion without vasoactives. Patient 2: 10 days to remit the marked necrosis. Well tolerated, initial slight drop in blood pressure, needing an increase of dopamine. Loss of the phalanges was avoided in both patients.Conclusion and RelevanceCommercialised 0.4% RNO in PTI was effective and safe in low birth weight premature newborns. However, it is necessary to be studied in more patients.Pharmacist’s role in the preparation, control and dispensing of medicines is essential, and its integration in the multidisciplinary team is crucial to ensure a quick response in emergency situations.References and/or AcknowledgementsConflict of InterestNo conflict of interest</abstract><cop>London</cop><pub>British Medical Journal Publishing Group</pub><doi>10.1136/ejhpharm-2023-eahp.90</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2047-9956
ispartof European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A42-A43
issn 2047-9956
2047-9964
language eng
recordid cdi_proquest_journals_2790018335
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Case reports
Conflicts of interest
Ischemia
Raw materials
Section 4: Clinical pharmacy services
title 4CPS-057 Searching for a treatment for peripheral tissue ischemia in newborns: a case report
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T14%3A20%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_j&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=4CPS-057%E2%80%85Searching%20for%20a%20treatment%20for%20peripheral%20tissue%20ischemia%20in%20newborns:%20a%20case%20report&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=D%C3%ADaz%20Perales,%20R&rft.date=2023-03-23&rft.volume=30&rft.issue=Suppl%201&rft.spage=A42&rft.epage=A43&rft.pages=A42-A43&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2023-eahp.90&rft_dat=%3Cproquest_bmj_j%3E2790018335%3C/proquest_bmj_j%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2790018335&rft_id=info:pmid/&rfr_iscdi=true